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Background: Bioimpedance analysis (BIA) has been reported as helpful in identifying hypervolemia. Observation
data showed that hypervolemic maintenance hemodialysis (MHD) patients identified using BIA methods have
higher mortality risk. However, it is not known if BIA-guided fluid management can improve MHD patients’ survival.
The objectives of the BOCOMO study are to evaluate the outcome of BIA guided fluid management compared
with standard care.
Methods: This is a multicenter, prospective, randomized, controlled trial. More than 1300 participants from
16 clinical sites will be included in the study. The enrolment period will last 6 months, and minimum length
of follow-up will be 36 months. MHD patients aged between 18 years and 80 years who have been on MHD for
at least 3 months and meet eligibility criteria will be invited to participate in the study. Participants will be
randomized to BIA arm or control arm in a 1:1 ratio. A portable whole body bioimpedance spectroscopy device
(BCM—Fresenius Medical Care D GmbH) will be used for BIA measurement at baseline for both arms of the study.
In the BIA arm, additional BCM measurements will be performed every 2 months. The primary intent-to-treat
analysis will compare outcomes for a composite endpoint of death, acute myocardial infarction, stroke or incident
peripheral arterial occlusive disease between groups. Secondary endpoints will include left ventricular wall
thickness, blood pressure, medications, and incidence and length of hospitalization.
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Discussions: Previous results regarding the benefit of strict fluid control are conflicting due to small sample sizes
and unstable dry weight estimating methods. To our knowledge this is the first large-scale, multicentre, prospective,
randomized controlled trial to assess whether BIS-guided volume management improves outcomes of MHD
patients. The endpoints of the BOCOMO study are of utmost importance to health care providers. In order to
obtain that aim, the study was designed with very careful important considerations related to the endpoints,
sample size, inclusion criteria, exclusion criteria and so on. For example, annual mortality of Beijing MHD patients
was around 10%. To reach statistical significance, the sample size will be very large. By using composite endpoint,
the sample size becomes reasonable and feasible. Limiting inclusion to patients with urine volume less than 800
ml/day the day before dialysis session will limit confounding due to residual renal function effects on the measured
parameters. Patients who had received BIS measurement within 3 months prior to enrolment are excluded as data
from such measurements might lead to protocol violation. Although not all patients enrolled will be incident
patients, we will record the vintage of dialysis in the multivariable analysis.
Trial registration: Current Controlled Trials NCT01509937
Keywords: Hemodialysis, Bioimpedance, Dry weight, Body composition monitor, Randomized controlled trialBackground
Intra-dialytic symptoms are common among patients on
maintenance hemodialysis (MHD). Adverse symptoms
are associated with both hypervolemia and hypovolemia.
Persistent hypervolemia causes hypertension, pulmonary
edema, and congestive heart failure, and leads to higher
mortality [1]. Compared with euvolemic patients, patients
with recurrent episodes of intra-dialytic hypovolemia
are at high risk of accelerated loss of residual renal func-
tion [2], vascular access function loss [3], brain atrophy
[4], mesenteric infarction [5], and hence, higher morbidity
and mortality [6,7].
Patients with high pre-dialysis (pre-HD) fluid overload
experience higher mortality risk compared with those
with less pre-HD fluid burden [1,8,9]. It is an important
strategy to reduce pre-HD fluid burden by restricting
inter-dialysis weight gain and to achieve euvolemic (dry)
weight post-HD by appropriate ultrafiltration. At present
there is no objective gold standard method for estimat-
ing target post-HD dry weight and clinical examination
is unreliable.
Several observational studies showed that strict post-
HD weight control was associated with better short term
outcome [10] or long term survival [11], but other stud-
ies associated strict fluid control with increased morbid-
ity and / or hospitalization [12,13]. These conflicting
results regarding the relationship between fluid control
and outcome mainly result from the lack of reliable
method for the assessment of individual euvolemia with
different studies used different definitions of dry weight
including un-tolerated blood volume decrease or ultrafil-
tration limit [14].
Bioimpedance spectroscopy (BIS) had long been used
to assess human body composition and has been vali-
dated by isotope dilution methods [15,16] and reference
body composition methods [16-18]. Recently, Wizemannet al. [1] used BIS to assess MHD patients’ fluid status,
and found that patients who had 15% or more expansion
of extra-cellular fluid (ECF) suffered higher mortality risk
compared with those had less than 15% ECF expansion.
BIS appears to be a promising and a valuable tool in
aiding dry weight estimation for MHD patients. Although
detailed BIS-based dry weight estimating methods were
published [10,19-21], and observational studies showed
the potential benefits of BIS [1,8], it is still not clear whe-
ther long-term outcome could be improved by regular dry
weight adjustment according to BIS based method.
We designed this multicenter, prospective, random-
ized and controlled trial to explore the effect of BIS




This is an open label, multicenter, prospective, rando-
mized controlled trial. The aim of the study is to assess
if BIS guided fluid management can improve long term
outcome in MHD patients. Body composition and hy-
dration state will be assessed with a portable whole body
bioimpedance spectroscopy device (BCM—Fresenius
Medical Care D GmbH). The study will involve 16 clin-
ical sites, enrolling more than 1300 participants. The
enrolment period will last approximately 6 months, with
a planned minimum 36 months follow-up period. Parti-
cipants will be randomized to two arms, the control arm
and BCM arm. Patients in both arms will receive BCM
measurement, but results from the BCM measurement
in the control group will be kept blinded to the investi-
gators. Participants in control group will be followed up
and their dry weights will be adjusted according to the
dialysis center’s standard clinical practice. Clinicians
managing participants in the BCM group, in addition
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and dry weight will be adjusted according to BCM out-
put data estimating overhydration and dry weight.
All of baseline demographics, clinical data, laboratory
data, regular BCM measurement, and ultrasonic cardio-
graph (UCG) data will be recorded on study case report
forms (CRFs).
The flow chart of the study is shown in Figure 1.
Study objectives
The objective of the study is to characterize the benefit
of BCM guided fluid management in MHD patients.
Primary objective
The primary objective of the study is to compare inci-
dence rate of a composite endpoint between BCM group
and control group. Participants reach the primary end-
point if at least one of the following occurs: (1) death,
(2) acute myocardial infarction, (3) cerebral thrombosis,
(4) cerebral hemorrhage, (5) peripheral arterial occlusive
disease. The diagnosis of endpoints will be made by the
Endpoint Committee.
Secondary objectives
Secondary objectives are to compare the following indi-
ces between BCM arm and control arm: (1) left ven-
tricular thickness and left ventricular ejection fraction,
(2) Pre-HD and post-HD blood pressure, (3) anti-
hypertensive medication, (4) hospitalization rate.
Study protocol
Inclusion criteria
Candidates must meet all of the following criteria to be
eligible for enrollment into the study: (1) diagnosis ofFigure 1 BOCOMO study Flow chart.end stage renal disease (ESRD) and need for MHD, (2)
age of 18 to 80 years old, (3) on MHD for at least
3 months, (4) dialysis frequency of at least 5 sessions per
2 weeks, not less than 4 hours per session and Kt/V at
least 1.2, (5) urine volume less than 800 mL per 24 hours
the day before dialysis session, (6) BIS not used within
recent 3 months, (7) dry weight regarded as adequate
according to the patient’s responsible doctor, (8) the abil-
ity to understand and willingness to sign an informed
consent statement.Exclusion criteria
Candidates meeting any one of the following criteria will
not be eligible to be included in the study: (1) acute in-
fection within prior month, (2) active rheumatic disease,
or current receipt of cortical steroid or cytotoxic medi-
cation, (3) uncontrolled neoplasm, (4) acute myocardial
infarction within prior month, (5) congestive heart fail-
ure (NYHA 3 – 4), (6) stroke within 3 prior months, (7)
metallic prosthesis (contraceptive device, artificial joint),
(8) amputation, (9) female of childbearing age who has a
pregnancy plan, or is pregnant, or is breast feeding, (10)
having a plan to reduce dialysis frequency, (11) having a
renal transplantation plan or planning to transfer to
peritoneal dialysis within 3 years, (12) participating or
planning to participate in other clinical trials which
would confound the current study.
Candidates meeting inclusion and exclusion criteria
will be included in the study after providing informed
consent. Study approval is obtained from the Institu-
tional Review Board, Peking University First Hospital.
This study is registered on ClinicalTrial.gov and has the
identification number NCT 01509937.
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Summary of data collection is listed in Table 1.Baseline data collection In brief, baseline data are col-
lected before initiation of BCM monitoring and include
demographics, ESRD treatment history, current vascular
access type, detailed comorbid conditions assessment,
current dialysis prescription and medications (oral, sub-
cutaneous and intravenous), CBC, routine laboratory
data, Kt/V, iPTH and hsCRP. UCG will also be per-
formed. BCM measurement will be done in participants
in both BCM arm and control arm. In the control
arm, BCM data will not be provided to patient care
provider. 24 hours urine volume will be recorded the
day before dialysis session. A physical examination will




Demographic information Once -
ESRD history1 Once -
Comorbidity2 Once -
Physical examination3 Once Every 2 months
Timed urine collection4 Once Every 2 months
CBC5 Once Every 3 months
Routine laboratory data6 Once Every 3 months
Kt/V Once Every 3 months
iPTH Once Every 3 months
hsCRP Once Every 3 months
UCG Once Every 12 months
BCM measurement Once Every 2 months in BCM arm
Dialysis prescription change7 Once Throughout the study period
Medication change8 Once Throughout the study period
New clinical event9 - Throughout the study period
Abbreviation: BOCOMO study, body composition monitor study; ESRD, end
stage renal disease; CBC, complete blood count; Kt/V, calculated using
Daugirdas single pool equation; iPTH, intact parathyroid hormone; hsCRP,
high sensitive C-reactive protein; UCG, ultrasonic cardiograph.
1ESRD history includes cause of ESRD, date of first dialysis, type of vascular
access.
2Detailed history of comorbidity will be assessed, including vascular access
events.
3Physical examination includes body weight, blood pressure, heart rate,
edema, pulmonary rale, before and after hemodialysis session.
424 hours urine volume collected the day before dialysis session will be
recorded.
5Consists of hemoglobin, white blood cell count, platelet count.
6Consists of albumin, pre-Albumin, creatinine, urea, potassium, sodium,
chloride, calcium, phosphate, bicarbonate, alkaline phosphatase (ALP), glucose,
triglycerides, total cholesterol, low density lipoprotein, high density
lipoprotein, brain natriuretic peptide (BNP).
7Any dialysis prescription change throughout the study period will be
recorded.
8Any medication change throughout the study period will be recorded.
9Any new clinical event throughout the study period will be recorded,
including hospitalization, new diagnosis, vascular access related event,
treatment of abnormal laboratory value, dry weight adjustment.Follow up data collection Physical examination and
urine volume collection will be performed every 2 months.
CBC, routine laboratory data, and Kt/V will be obtained
every 3 months. iPTH and hsCRP will be measured every
3 months. UCG will be performed every 12 months.
BCM measurement will be performed every 2 months
in BCM arm, data will be recorded and provided to the
care provider.
Dry Weight Adjustment Strategy
All participants will be educated to reduce inter-dialysis
weight gain to less than 5% body weight.
For participants in the control arm, dry weight will be
adjusted according to the clinical site’s standard clinical
practice.
For participants in the BCM arm, dry weight will be
adjusted according to the BCM estimates of overhydra-
tion and normovolemic weight. During each dialysis
session, participants’ dry weight will be increased or
decreased toward BCM reported dry weight. The incre-
ment or decrement of dry weight will not be greater
than 0.5 Kg within a single dialysis session. Thus, in this
arm participants’ dry weights will be gradually adjusted
to BCM reported value. If ultrafiltration is not tolerated
because of hypovolemia based on symptoms and signs,
such as muscle cramps, need for excessive saline,
or symptomatic hypotension, adverse events will be
recorded, and the actual dry weight will be adjusted by
plus 0.5 Kg. If participants experience hypervolemic clin-
ical episodes, such as hypertension related symptom,
congestive heart failure, pulmonary edema, adverse
events will also be recorded. If a patient experiences the
same adverse effect of dry weight change for two con-
secutive visits, the patient will be removed from the
study because of adverse event.
Dry weight adjustment flow chart in the BCM arm is
shown in Figure 2.
Clinical events
Dialysis prescription change Dialysis prescription may
be changed according to clinical site’s standard practice
including changes of dialyzer, blood flow rate, dialysate
flow rate, frequency of dialysis, dialysis modality (con-
ventional hemodialysis, high flux dialysis, hemofiltration,
hemodiafiltration, and in combination of blood perfu-
sion). Kt/V will remain not less than 1.2 despite dialysis
prescription change. Dialysis prescription change is
regarded as a clinical event and will be recorded.
Medications change Medications (oral, subcutaneous and
intravenous drug administration) can be changed according
to clinical site’s practice, this including anti-hypertensives,
active vitamin D and its analogues, erythrocyte stimulating
Figure 2 Dry weight adjustment flow chart in the BCM arm.
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is regarded as a clinical event and will be recorded.
New diagnosis Any newly emerged diagnosis is regarded
as a clinical event and will be recorded; hypotension and
related clinical episode, hypertension and related clinical
episode, pulmonary infection, diarrhea, angina pectoris,
myocardial infarction, ischemic and hemorrhagic stroke,
peripheral arterial occlusive disease, newly diagnosed
neoplasm.
All deaths will be recorded as to date of death and cause.
Vascular access event Vascular access bleeding, throm-
bosis or malfunction will be recorded.
Dry weight change Each step of weight adjustment will
be recorded.
Hospitalization Hospitalization will be recorded, in-
cluding diagnosis leading to hospitalization, date of
hospitalization, length of stay, and outcome.
Abnormal laboratory value If a procedure is performed
to deal with abnormal laboratory value, the abnormal
laboratory value is a clinical event and will be recorded.
Data censoring The following participants are censored:
(1) transfer to peritoneal dialysis, (2) renal transplantation,
(3) becomes pregnant, (4) receives metal implantation, or
any other reasons that make BCM measurement impos-
sible, (5) limb amputation, (6) withdrawal of consent, (7)
receives any forms of BIS measurement other than those
specified by the trial protocol, (8) relocates to other clin-
ical site, (9) investigator requests the participant be with-
drawn from the study.Safety issue
The clinical use of BIS method had been approved by
State of Food and Drug Administration (SFDA). As one
form of BIS method, BCM device is widely used in Eur-
ope. BIS inject weak alternating current into human
body, which cause no harm to human body.
Statistical analysis
Study hypotheses
This study is designed to test the primary hypotheses
that patients receiving BCM guided fluid management
have lower rate for the composite endpoint of mortality,
cardiovascular and cerebrovascular events compared
with patients receiving fluid management according to
clinical site’s standard care. The secondary hypotheses
that will be tested are that patients receiving BCM meas-
urement have (1) lower left ventricular thickness and
higher left ventricular ejection fraction, (2) better blood
pressure control, (3) less anti-hypertensive medication,
(4) lower hospitalization rate.
Sample size calculation
Literature search failed to identify a study of similar
design to this one. In an observational study by Wizemann
et al. [1] of 269 MHD patients the patients were divided
into hypervolemic group if their ECF was 15% higher than
normal or normohydrated group if less than 15%. The
patients were followed for an average 3.5 years. There was
41% death in the hypervolemic group, and 30% death in
normohydrated group. Relative risk of death was 36.6%
higher in hypervolemic group than in the other.
According to data from Beijing Hemodialysis Quality
Control and Improvement Center, the annual mortality
rate of Beijing MHD patients is around 10%, it is esti-
mated that 3 year mortality to be 30%. It is also esti-
mated that the rate of composite endpoint within 3 year
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BCM guided fluid management will reduce the 3-year
composite endpoint rate from 40% to 32% (20% relative
risk reduction). To reach statistical significance with
α < 0.05 and 1-β > 80%, the sample size required is 1128.
Allowing for a 20% loss-to-follow-up, the total sample
size planned is 1354.
Analytical method
Primary endpoint The primary analysis will be an
intent-to-treat analysis comparing composite endpoint
between the BCM and the control arms. The intent-to-
treat population is defined as all enrolled study partici-
pants. For this analysis, the follow-up time begins from
the enrollment date to the composite endpoint, loss to
follow-up, or end of study.
Multivariate Cox proportional hazards regression
models will be used for analysis of the risk of death com-
paring BCM and control arms, with adjustment for age,
sex, dialysis vintage, primary cause of ESRD, comorbid
conditions, and other characteristics that may be asso-
ciated with increased risk of death, such as inter-dialysis
weight gain, hypertension and hsCRP.
Secondary endpoint The following 3 secondary end-
points will be compared between BCM and control arms
using grouped t-test, and within group trend will also be
analyzed: (1) left ventricular thickness and left ventricu-
lar ejection fraction, (2) pre-HD and post-HD blood
pressure, (3) anti-hypertensive medication.
The secondary endpoint of incident rate of hospitaliza-
tion will be compared between BCM arm and control arm
using general Linear Model with Poisson regression.
Interim analysis The final analysis for primary endpoint
and secondary analysis will be performed after comple-
tion of study.
Interim analysis is planned 1 year and 2 years after
study initiation. The purpose of interim analysis
includes: (1) adjustment of sample size according to col-
lected real data, (2) early termination of study if statisti-
cally significance reached comparing primary endpoint
between BCM arm and control arm, (3) early termination
of study if incidence rate of fluid management related
adverse events is significantly high in the BCM arm.
Discussions
Strengths
Previous results regarding the benefit of strict fluid con-
trol are conflicting due to small sample sizes and un-
stable dry weight estimating methods. To our knowledge
this is the first large-scale, multicentre, prospective, ran-
domized controlled trial to assess whether BIS-guidedvolume management improves outcomes of MHD
patients. The endpoints of the BOCOMO study are of
utmost importance to health care providers.
About the design
Inclusion and exclusion criteria
(1) Only MHD patients who had been on MHD for at
least 3 months are eligible. This is because patients with
dialysis vintage less than 3 months are more likely to
be hemodynamically unstable. Additionally, this criterion
reduces the likelihood that pre-ESRD factors will be
introduced into the study confounding the primary re-
sult. (2) Limiting inclusion to patients with urine volume
less than 800 ml/day the day before dialysis session will
limit confounding due to residual renal function effects
on the measured parameters. (3) Patients who had
received BIS measurement within 3 months prior to
enrolment are excluded as data from such measure-
ments might lead to protocol violation.
Changes of dialysis prescription and medications
Fluid status change will definitely lead to physiological
changes of the body. It is reasonable that some clinical
parameter will change, like blood pressure, hemoglobin,
hsCRP, BNP. So it is reasonable to allow dialysis pre-
scription and medications change, which will serve as
one of the secondary endpoints.
Endpoint and sample size
Annual mortality of Beijing MHD patients was around
10%. To reach statistical significance, the sample size
will be very large. By using composite endpoint, the
sample size becomes reasonable and feasible.
Dry weight adjustment in BCM arm
“Real dry weight” is unknown in BOCOMO study. BCM
reported dry weight might by significantly higher or
lower than the real dry weight, which will lead to hyper-
volemia related acute symptoms and hypovolemia
related acute symptoms, respectively. They will also
worsen patients’ long-term outcome. In these kinds of
conditions, adverse events attributes to BCM arm will
be recorded.
Another issue regarding dry weight adjustment in
BCM arm is the amount of each dry weight increase or
decrease. Large amount of dry weight change is not
allowed because significant dry weight increase or de-
crease during one HD session will lead to dramatic
blood volume increase or decrease during HD session
and associated clinical manifestation.
Limitations
There are several limitations of the BOCOMO study: (1)
using composite endpoint instead of mortality, (2) inclusion
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dialysis vintage will be included in multivariable analysis),
(3) most clinical sites are located in Beijing.
Conclusion
In summary, the BOCOMO study has the potential to
be the largest and the first prospective randomized con-
trolled trial to evaluate the long term clinical benefit of
BIS-guided fluid management in MHD patients. The
aim of the study is to validate whether BIS based dry
weight adjustment decrease incidence composite end-
point of death, acute myocardial infarction, stroke, and
peripheral arterial disease. The result will be of great
clinical importance.
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